Developing drugs for developing countries.
Abstract
Infectious and parasitic diseases create enormous health burdens, but because most
of the people suffering from these diseases are poor, little is invested in developing
treatments. We propose that developers of treatments for neglected diseases receive
a "priority review voucher." The voucher could save an average of one year of U.S.
Food and Drug Administration (FDA) review and be sold by the developer to the manufacturer
of a blockbuster drug. In a well-functioning market, the voucher would speed access
to highly valued treatments. Thus, the voucher could benefit consumers in both developing
and developed countries at relatively low cost to the taxpayer.
Type
Journal articleSubject
Anti-Infective AgentsAntiparasitic Agents
Developing Countries
Drug Approval
Drug Industry
Health Services Accessibility
Humans
Legislation, Drug
Marketing
Orphan Drug Production
Patents as Topic
Program Development
Reimbursement, Incentive
United States
United States Food and Drug Administration
Permalink
https://hdl.handle.net/10161/7017Published Version (Please cite this version)
10.1377/hlthaff.25.2.313Publication Info
Ridley, David; & Moe, Jeffrey (2006). Developing drugs for developing countries. Health Aff (Millwood), 25(2). pp. 313-324. 10.1377/hlthaff.25.2.313. Retrieved from https://hdl.handle.net/10161/7017.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Jeffrey Moe
Adjunct Professor of Global Health
David Blaine Ridley
Professor of the Practice of Business Administration
David Ridley is the Faculty Director for Health Sector Management at Duke University’s
Fuqua School of Business. He studies health care innovation, production, and prices. He
is especially interested in how to encourage development of drugs and vaccines for
neglected diseases. David was the lead author of the paper proposing the <a href="http://priori
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info